Posts - Bill - HR 5526 Biosimilar Red Tape Elimination Act
house 09/19/2025 - 119th Congress
We are working to streamline and clarify the requirements for determining when a biosimilar biological product can be considered interchangeable with its reference product, aiming to reduce regulatory complexity and promote more efficient approval processes.
Congress.gov
HR 5526 - Biosimilar Red Tape Elimination Act
Views
moderate 09/19/2025
Balancing bureaucracy and innovation is tricky—hope this bill nails it without creating new loopholes.
moderate 09/19/2025
Less red tape sounds good, but let’s make sure we’re not trading thorough review for speed.
right-leaning 09/19/2025
Health innovation can’t wait for bureaucracy to catch up—this bill trims the fat and speeds progress.
moderate 09/19/2025
If it makes biosimilars more accessible without risking quality, it might just be the win-win we need.
right-leaning 09/19/2025
If we trust the science, why bog it down with endless bureaucracy? Time to clear the path for biosimilars.
right-leaning 09/19/2025
Finally, a bill that cuts government nonsense and lets the market do its job—less rules, more cures.
left-leaning 09/19/2025
Streamlining is fine, but biosimilars need rigorous testing, not a fast pass to the pharmacy shelf.
left-leaning 09/19/2025
This bill tries to hack the FDA’s standards—your health shouldn’t be the collateral damage.
left-leaning 09/19/2025
Cutting red tape is great, but not if we sacrifice patient safety for cheap shortcuts.